Study Evaluating Venlafaxine ER in Adults With Panic Disorder

A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00038896

Enrollment

343

Registered

2002-06-07

Start date

2001-04-30

Completion date

2002-12-31

Last updated

2009-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Panic Disorder

Keywords

Panic, Disorder

Brief summary

The primary objective of this study is to determine the efficacy, safety, and tolerability of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in the treatment of adult outpatients with panic disorder (PD) in a placebo-controlled phase III study.

Interventions

DRUGVenlafaxine ER

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* A male or female outpatient * Be at least 18 years of age and legal age of consent * Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before study day 1

Exclusion criteria

* Treatment with venlafaxine (IR or ER) within 6 months of study day 1 * Known hypersensitivity to venlafaxine (IR or ER) or related compounds * History or presence of any clinically important hepatic, renal, or other medical disease that might compromise the study or be detrimental to the patient (eg, clinically important cardiac arrhythmia, unstable diabetes, carcinoma \[except basal cell epithelioma\], uncontrolled hypertension)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026